Phase II study of dasatinib (DA) in combination with chemotherapy and allogeneic stem cell transplantation (SCT) for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia by Japan Acute Leukemia Study Group (JALSG Ph+ALL213)

Trial Profile

Phase II study of dasatinib (DA) in combination with chemotherapy and allogeneic stem cell transplantation (SCT) for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia by Japan Acute Leukemia Study Group (JALSG Ph+ALL213)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Dasatinib (Primary) ; Antineoplastics; Prednisolone
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 Nov 2013 New trial record
    • 01 Nov 2013 Status changed from not yet recruiting to recruiting as rreported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top